Precision BioSciences

$11.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.38 (-3.30%) Today
-$0.13 (-1.17%) As of 1:07 PM UTC after-hours

Why Robinhood?

You can buy or sell DTIL and other stocks, options, and ETFs commission-free!

About DTIL

Precision BioSciences, Inc. Common Stock, also called Precision BioSciences, is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC. The listed name for DTIL is Precision BioSciences, Inc. Common Stock.

CEO
Matthew R. Kane
Employees
199
Headquarters
Durham, North Carolina
Founded
2006
Market Cap
546.55M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.22M
High Today
$12.18
Low Today
$11.05
Open Price
$11.70
Volume
962.49K
52 Week High
$16.60
52 Week Low
$4.46

DTIL Earnings

-$0.66
-$0.44
-$0.22
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 10, Pre-Market

You May Also Like

GXG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure